FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200472783> ?p ?o ?g. }

• W4200472783 endingPage "175" @default.
• W4200472783 startingPage "165" @default.
• W4200472783 abstract "Background Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without prior intravesical Bacillus Calmette-Guerin (BCG), who received ICI for aUC, hypothesizing that prior intravesical BCG would be associated with worse outcomes. Patients and Methods We performed a retrospective cohort study across 25 institutions in US and Europe. We compared observed response rate (ORR) using logistic regression; progression-free survival (PFS) and OS using Kaplan-Meier and Cox proportional hazards. Analyses were stratified by treatment line (first line/salvage) and included multivariable models adjusting for known prognostic factors. Results A total of 1026 patients with aUC were identified; 614, 617, and 638 were included in ORR, OS, PFS analyses, respectively. Overall, 150 pts had history of prior intravesical BCG treatment. ORR to ICI was similar between those with and without prior intravesical BCG exposure in both first line and salvage settings (adjusted odds radios 0.55 [P= .08] and 1.65 [P= .12]). OS (adjusted hazard ratios 1.05 [P= .79] and 1.13 [P= .49]) and PFS (adjusted hazard ratios 1.12 [P= .55] and 0.87 [P= .39]) were similar between those with and without intravesical BCG exposure in first line and salvage settings. Conclusion Prior intravesical BCG was not associated with differences in response and survival in patients with aUC treated with ICI. Limitations include retrospective nature, lack of randomization, presence of selection and confounding biases. This study provides important preliminary data that prior intravesical BCG exposure may not impact ICI efficacy in aUC." @default.
• W4200472783 created "2021-12-31" @default.
• W4200472783 creator A5001186829 @default.
• W4200472783 creator A5003722043 @default.
• W4200472783 creator A5004819903 @default.
• W4200472783 creator A5009737345 @default.
• W4200472783 creator A5010692293 @default.
• W4200472783 creator A5011367118 @default.
• W4200472783 creator A5011709879 @default.
• W4200472783 creator A5014940812 @default.
• W4200472783 creator A5024147987 @default.
• W4200472783 creator A5024278705 @default.
• W4200472783 creator A5026717218 @default.
• W4200472783 creator A5027255838 @default.
• W4200472783 creator A5028180083 @default.
• W4200472783 creator A5029144224 @default.
• W4200472783 creator A5031234862 @default.
• W4200472783 creator A5036620887 @default.
• W4200472783 creator A5040044206 @default.
• W4200472783 creator A5044677538 @default.
• W4200472783 creator A5044876102 @default.
• W4200472783 creator A5045869380 @default.
• W4200472783 creator A5048398263 @default.
• W4200472783 creator A5049071296 @default.
• W4200472783 creator A5049546835 @default.
• W4200472783 creator A5049657362 @default.
• W4200472783 creator A5050237256 @default.
• W4200472783 creator A5052069729 @default.
• W4200472783 creator A5053501357 @default.
• W4200472783 creator A5053588971 @default.
• W4200472783 creator A5055464636 @default.
• W4200472783 creator A5056466515 @default.
• W4200472783 creator A5058267733 @default.
• W4200472783 creator A5058325420 @default.
• W4200472783 creator A5063690225 @default.
• W4200472783 creator A5067386940 @default.
• W4200472783 creator A5068365064 @default.
• W4200472783 creator A5068543301 @default.
• W4200472783 creator A5070016877 @default.
• W4200472783 creator A5079344689 @default.
• W4200472783 creator A5080507578 @default.
• W4200472783 creator A5080866168 @default.
• W4200472783 creator A5081014476 @default.
• W4200472783 creator A5084523168 @default.
• W4200472783 creator A5084909001 @default.
• W4200472783 creator A5088645680 @default.
• W4200472783 creator A5090241399 @default.
• W4200472783 creator A5091309316 @default.
• W4200472783 creator A5091681745 @default.
• W4200472783 date "2022-04-01" @default.
• W4200472783 modified "2023-10-01" @default.
• W4200472783 title "Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin" @default.
• W4200472783 cites W2002045993 @default.
• W4200472783 cites W2027945742 @default.
• W4200472783 cites W2093274439 @default.
• W4200472783 cites W2132379894 @default.
• W4200472783 cites W2152206210 @default.
• W4200472783 cites W2162130153 @default.
• W4200472783 cites W2333193688 @default.
• W4200472783 cites W2895579856 @default.
• W4200472783 cites W2921309965 @default.
• W4200472783 cites W2921560039 @default.
• W4200472783 cites W2943108118 @default.
• W4200472783 cites W2944434778 @default.
• W4200472783 cites W2987436342 @default.
• W4200472783 cites W2989576250 @default.
• W4200472783 cites W3010696323 @default.
• W4200472783 cites W3035939364 @default.
• W4200472783 cites W3087464965 @default.
• W4200472783 cites W3087466624 @default.
• W4200472783 cites W3118924526 @default.
• W4200472783 cites W3151253846 @default.
• W4200472783 doi "https://doi.org/10.1016/j.clgc.2021.12.012" @default.
• W4200472783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35078711" @default.
• W4200472783 hasPublicationYear "2022" @default.
• W4200472783 type Work @default.
• W4200472783 citedByCount "4" @default.
• W4200472783 countsByYear W42004727832022 @default.
• W4200472783 countsByYear W42004727832023 @default.
• W4200472783 crossrefType "journal-article" @default.
• W4200472783 hasAuthorship W4200472783A5001186829 @default.
• W4200472783 hasAuthorship W4200472783A5003722043 @default.
• W4200472783 hasAuthorship W4200472783A5004819903 @default.
• W4200472783 hasAuthorship W4200472783A5009737345 @default.
• W4200472783 hasAuthorship W4200472783A5010692293 @default.
• W4200472783 hasAuthorship W4200472783A5011367118 @default.
• W4200472783 hasAuthorship W4200472783A5011709879 @default.
• W4200472783 hasAuthorship W4200472783A5014940812 @default.
• W4200472783 hasAuthorship W4200472783A5024147987 @default.
• W4200472783 hasAuthorship W4200472783A5024278705 @default.
• W4200472783 hasAuthorship W4200472783A5026717218 @default.
• W4200472783 hasAuthorship W4200472783A5027255838 @default.
• W4200472783 hasAuthorship W4200472783A5028180083 @default.
• W4200472783 hasAuthorship W4200472783A5029144224 @default.
• W4200472783 hasAuthorship W4200472783A5031234862 @default.
• W4200472783 hasAuthorship W4200472783A5036620887 @default.
• W4200472783 hasAuthorship W4200472783A5040044206 @default.
• W4200472783 hasAuthorship W4200472783A5044677538 @default.

• next